Stockreport

Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing [Seeking Alpha]

Tenax Therapeutics, Inc.  (TENX) 
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.tenaxthera.com
PDF TNX-103, targeting PH-HFpEF, shows a high probability of Phase 3 success with a 65% PoS and strong Phase 2 efficacy signals. Valuation assumes $500M peak sales by 203 [Read more]